BRAF V600E mutation and papillary thyroid cancer

JAMA

Volumn 310, Issue 5, 2013, Pages 535-

  Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; VALINE;

AGE; AGGRESSIVE TUMOR BEHAVIOR; BRAF GENE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; DISEASE ASSOCIATION; DISEASE COURSE; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; LETTER; ONCOLOGICAL PARAMETERS; PAPILLARY THYROID CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; THYROID CANCER; CARCINOMA; FEMALE; GENETICS; MALE; MORTALITY; NOTE; NUCLEOTIDE SEQUENCE; THYROID TUMOR;

CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84881235027     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.8592     Document Type: Letter

References (4)

1. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493-1501.
2. Cappola AR, Mandel SJ. Molecular testing in thyroid cancer: BRAF mutation status and mortality. JAMA. 2013;309(14):1529-1530.
3. Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009;27(18):2977-2982.
4. Elisei R, Viola D, Torregrossa L, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97(12):4390-4398.